Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow (FCF).
PFIZER Free Cash Flow Analysis
Free cash flow, a measure commonly used by analysts to assess a company's profitability, represents the cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
The Free Cash Flow is calculated using a number of methods including using Operating Cash Flow. Following is the formula to calculate Free Cash Flow based on Operating Cash Flow.
Free Cash Flow = Operating Cash Flow - Capital Expenditures
Using above formula to calculate Free Cash Flow for Pfizer Limited (PFIZER), the free cash flow value is 6.32B.
All amounts in INR
Pfizer Limited has a positive free cash flow as per the latest annual Cash flow statement released by the company. Positive free cash flow is cruscial for the financial health of a company, which can be used to pay dividends, expand operations, and deleverage its balance sheet (i.e., reduce debt).
PFIZER Cash Flow Statement History
Following table shows the history of Cash Flow Statements sheet for Pfizer Limited (NSE:PFIZER).
| 31 Mar 2022 | 31 Mar 2023 | 31 Mar 2024 | 31 Mar 2025 | |
|---|---|---|---|---|
| Total Cash From Operating Activities | 6,670,800,000 | 3,556,800,000 | 2,568,400,000 | 6,597,500,000 |
| Capital Expenditures | [object Object] | [object Object] | [object Object] | [object Object] |
| Investing Cash Flow | -5,750,200,000 | -360,500,000 | 537,000,000 | -713,400,000 |
| Financing Cash Flow | -1,805,100,000 | -3,457,900,000 | -2,351,400,000 | -2,053,400,000 |
| Free Cash Flow | 6,517,700,000 | 2,907,000,000 | 2,379,100,000 | 6,316,000,000 |
| Stock Based Compensation | 117,700,000 | 127,000,000 | 144,500,000 | 136,600,000 |
| Taxes Refund Paid | -2,259,200,000 | -3,025,800,000 | -1,538,200,000 | -1,562,200,000 |
| Net P P E Purchase And Sale | -132,500,000 | -637,600,000 | 339,700,000 | 1,237,300,000 |
| Sale Of P P E | 20,600,000 | 12,200,000 | 529,000,000 | 1,518,800,000 |
| Change In Other Current Liabilities | 70,700,000 | -294,000,000 | -552,400,000 | 219,400,000 |
| Beginning Cash Position | ||||
| End Cash Position | ||||
| Changes In Cash | ||||
| Other Non Cash Items | ||||
| Change In Other Current Assets | ||||
| Cash Dividends Paid | ||||
| Gain Loss On Sale Of P P E | ||||
| Purchase Of P P E | ||||
| Operating Cash Flow | 6,670,800,000 | 3,556,800,000 | 2,568,400,000 | 6,597,500,000 |
| Capital Expenditure | -153,100,000 | -649,800,000 | -189,300,000 | -281,500,000 |
| Net Income From Continuing Operations |